NOVO NORDISK -B- (NOVO-B.CO)
-Copenhagen 967.50 
1.50(0.15%) May 24, 10:59AM EDT
| Prev Close: | 969.00 |
|---|
| Open: | 978.00 |
|---|
| Bid: | 967.50 |
|---|
| Ask: | 968.50 |
|---|
| 1y Target Est: | N/A |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 962.50 - 989.00 |
|---|
| 52wk Range: | 770.00 - 1,100.00 |
|---|
| Volume: | 801,605 |
|---|
| Avg Vol (3m): | 657,367 |
|---|
| Market Cap: | N/A |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | N/A |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in DKK.
Headlines
- Novo obesity drug could launch in U.S. end 2014at Reuters(Fri, May 24)
- Novo sees US obesity drug launch end 2014/start of 2015-CSOat Reuters(Fri, May 24)
- NORDIC STOCKS - Factors to watch on May 24at Reuters(Fri, May 24)
- Novo Nordisk says obesity drug trial confirms weight lossat Reuters(Thu, May 23)
- Novo Nordisk A/S : Novo Nordisk reports 8% weight loss in phase 3a obesity trial with liraglutide 3 mgMarketwired(Thu, May 23)
- BRIEF-Novo Nordisk reports headline results for liraglutide trialat Reuters(Thu, May 23)
- Novo Nordisk A/S - Share repurchase programmeMarketwired(Tue, May 21)
- Novo holding company buys Norwegian Xelliaat Reuters(Tue, May 21)
- Novo Nordisk reports positive results from first phase 3 trial with long-acting factor IX for treatment of haemophilia BMarketwired(Fri, May 17)
- Novo Nordisk says completes haemophilia drug trialat Reuters(Fri, May 17)
- NORDIC STOCKS - Factors to watch on May 17at Reuters(Fri, May 17)
- Novo Nordisk A/S - Share Repurchase ProgrammeMarketwired(Mon, May 13)
- REUTERS SUMMIT-Faster drug approvals a tonic for pharma industryat Reuters(Wed, May 8)
- Novo Nordisk A/S - Share repurchase programmeMarketwired(Fri, May 3)
- Novo Nordisk A/S purchases B shares worth DKK 2.5 billion from Novo A/S as part of the on-going share repurchase programmeMarketwired(Fri, May 3)
Reports
- No Reports available for NOVO-B.CO at this time.
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | N/A |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
()
: | N/A |
|---|
| Quarterly EPS Est
()
: | N/A |
|---|
| Mean Recommendation*: | N/A |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
No business summary available forNOVO-B.CO.